These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 18388148

  • 21. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A, Inaba M, Furumitsu Y, Okamoto K, Yukioka K, Goto H, Nishizawa Y.
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [Abstract] [Full Text] [Related]

  • 22. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
    Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, Nagasawa H, Suzuki K, Matsubara K, Takeuchi T.
    Biochem Biophys Res Commun; 2009 Sep 18; 387(2):261-5. PubMed ID: 19577537
    [Abstract] [Full Text] [Related]

  • 23. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
    Oliveira RD, Fontana V, Junta CM, Marques MM, Macedo C, Rassi DM, Passos GA, Donadi EA, Louzada-Junior P.
    J Rheumatol; 2012 Aug 18; 39(8):1524-32. PubMed ID: 22753658
    [Abstract] [Full Text] [Related]

  • 24. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar 18; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

  • 25. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D.
    Arthritis Rheum; 2003 Jul 18; 48(7):1849-52. PubMed ID: 12847678
    [Abstract] [Full Text] [Related]

  • 26. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec 18; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 27. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity.
    Yazici S, Yazici M, Erer B, Erer B, Calik Y, Ozhan H, Ataoglu S.
    Platelets; 2010 Dec 18; 21(2):122-5. PubMed ID: 20050760
    [Abstract] [Full Text] [Related]

  • 28. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec 18; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 29. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M.
    J Autoimmun; 2008 Sep 18; 31(2):175-9. PubMed ID: 18707846
    [Abstract] [Full Text] [Related]

  • 30. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun 18; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 31. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec 18; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 32. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.
    Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y.
    Ann Rheum Dis; 2008 Mar 18; 67(3):380-8. PubMed ID: 17660216
    [Abstract] [Full Text] [Related]

  • 33. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.
    van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, Tak PP, Verweij CL.
    Genes Immun; 2010 Dec 18; 11(8):622-9. PubMed ID: 20555356
    [Abstract] [Full Text] [Related]

  • 34. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis.
    Wittkowski H, Foell D, af Klint E, De Rycke L, De Keyser F, Frosch M, Ulfgren AK, Roth J.
    Ann Rheum Dis; 2007 Aug 18; 66(8):1020-5. PubMed ID: 17223658
    [Abstract] [Full Text] [Related]

  • 35. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.
    Ann Rheum Dis; 2008 May 18; 67(5):620-4. PubMed ID: 17720725
    [Abstract] [Full Text] [Related]

  • 36. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.
    Markham T, Mathews C, Rogers S, Mullan R, Bresnihan B, Fitzgerald O, Veale DJ, Fearon U.
    Br J Dermatol; 2006 Dec 18; 155(6):1191-6. PubMed ID: 17107388
    [Abstract] [Full Text] [Related]

  • 37. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, Ferraccioli G.
    Clin Pharmacol Ther; 2006 Sep 18; 80(3):275-81. PubMed ID: 16952494
    [Abstract] [Full Text] [Related]

  • 38. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 18; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 39. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM.
    Ann Rheum Dis; 2005 Apr 18; 64(4):537-43. PubMed ID: 15769913
    [Abstract] [Full Text] [Related]

  • 40. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR, Engstrand S, Berglin E, Johnson O.
    Scand J Rheumatol; 2006 Apr 18; 35(2):107-11. PubMed ID: 16641043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.